Table 1. Patient Characteristics.
| Characteristic | Total study cohort, No. (%) (N = 217) | Group 1: first primary NSCLC, No. (%) (n = 79) | Group 2: new primary or multiple synchronous NSCLC, No. (%) (n = 67) | Group 3: lung metastases, No. (%) (n = 71) |
|---|---|---|---|---|
| Age, median (IQR), y | 72 (64-80) | 74 (68-81) | 73 (66-81) | 65 (56-75) |
| Sex | ||||
| Male | 129 (59) | 45 (57) | 44 (66) | 40 (56) |
| Female | 88 (41) | 34 (43) | 23 (34) | 31 (44) |
| ECOG performance status | ||||
| 0 | 40 (20) | 5 (7) | 19 (31) | 16 (24) |
| 1 | 112 (56) | 37 (52) | 32 (52) | 43 (63) |
| 2 | 36 (18) | 20 (28) | 10 (16) | 6 (9) |
| 3 | 12 (6) | 9 (13) | 0 (0) | 3 (4) |
| Unknown | 17 (8) | 8 (10) | 6 (9) | 3 (4) |
| Smoking history | ||||
| Current | 26 (12) | 16 (20) | 6 (9) | 4 (6) |
| Former | 124 (57) | 53 (67) | 46 (69) | 25 (35) |
| Never | 58 (27) | 8 (10) | 14 (21) | 36 (51) |
| Unknown | 9 (4) | 2 (3) | 1 (1) | 6 (8) |
| Treatment courses, No. | 240 | 79 | 82 | 79 |
| Biopsy-proven | 214 (89) | 76 (96) | 68 (83) | 70 (89) |
| Medically operablea | N/A | 17 (22) | N/A | N/A |
| Histological characteristics | ||||
| Squamous cell carcinoma | 41 (17) | 17 (22) | 11 (13) | 13 (16) |
| Adenocarcinoma | 145 (60) | 50 (63) | 55 (67) | 40 (51) |
| Large cell carcinoma | 3 (1) | 2 (3) | 0 (0) | 1 (1) |
| Other | 41 (17) | 7 (9) | 10 (12) | 24 (30) |
| Unknown | 10 (4) | 3 (4) | 6 (7) | 1 (1) |
| Primary site, No. | N/A | All lung | All lung | Lung, 31; colorectal, 17; head and neck, 5; breast, 3; skin, 2; other, 21 |
| Tumors, No. | 285 | 79 | 103 | 103 |
| Location, size (dose)b | ||||
| Peripheral, 0-10 cm3 (25 Gy in 1 fx) | 159 (56) | 35 (44) | 72 (70) | 52 (50) |
| Peripheral, 0-10 cm3 colorectal (50 Gy in 4 fx) | 10 (4) | 0 (0) | 0 (0) | 10 (10) |
| Peripheral, 10.1-30 cm3 (50 Gy in 4 fx) | 31 (11) | 16 (20) | 7 (7) | 8 (8) |
| Peripheral, >30 cm3 (54 Gy in 3 fx) | 11 (4) | 7 (9) | 2 (2) | 2 (2) |
| Central, 0-10 cm3 (40 Gy in 4 fx) | 34 (12) | 8 (10) | 14 (14) | 12 (12) |
| Central, 0-10 cm3 colorectal (50 Gy in 4 fx) | 7 (2) | 0 | 0 | 7 (7) |
| Central, 10.1-30 cm3 (50 Gy in 4 fx) | 25 (9) | 8 (10) | 6 (6) | 11 (11) |
| Central, >30 cm3 (60 Gy in 8 fx) | 8 (3) | 5 (6) | 2 (2) | 1 (1) |
| AJCC 7th edition stage | ||||
| T1aN0M0 | N/A | 29 (37) | 66 (64) | N/A |
| T1bN0M0 | N/A | 26 (33) | 24 (23) | N/A |
| T2aN0M0 | N/A | 22 (28) | 9 (9) | N/A |
| T2bN0M0 | N/A | 2 (3) | 4 (4) | N/A |
Abbreviations: AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group; fx, fractions; NSCLC, non–small cell lung cancer.
a
Operable status was identified by whether a patient was fit to receive anatomical resection with or without lymph node dissection, using pulmonary function test results and functional status.
b
Three patients received a dose different from the assigned dose for their location and size combination; see Results section.